Two Sigma Advisers
CLYM

Two Sigma Advisers’s Climb Bio CLYM Stock Holding History

Two Sigma Advisers’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-124,700
Closed -$499K – 2272
2025
Q4 		$499K Buy
124,700
+43,800
+54% +$105K ﹤0.01% 1783
2025
Q3 		$163K Sell
80,900
-14,000
-15% -$26K ﹤0.01% 2173
2025
Q2 		$118K Sell
94,900
-19,100
-17% -$23.8K ﹤0.01% 2192
2025
Q1 		$139K Buy
114,000
+2,300
+2% +$3.73K ﹤0.01% 2200
2024
Q4 		$201K Buy
+111,700
New +$404K ﹤0.01% 2124

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Two Sigma Advisers's CLYM Position: Q1 2026 in Review

Two Sigma Advisers sold out of Climb Bio (CLYM) in Q1 2026, closing a stake of 124,700 shares — an estimated $499K sold.

Two Sigma Advisers first reported a position in CLYM in Q4 2024 and held it in 5 quarters. The position peaked at $499K in Q4 2025. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Two Sigma Advisers reported no remaining Climb Bio position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 124,700 Climb Bio shares in Q1 2026, an estimated $499K.
  • Two Sigma Advisers first reported a position in Climb Bio in Q4 2024 and held it in 5 quarters.
  • Two Sigma Advisers's Climb Bio position peaked at $499K in Q4 2025.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.